Oxurion NV (OXUR BR) stock market data APIs
€0.0024
0(0%)
as of September 10, 2026
Try our APIs with
free plan!
Oxurion NV Financial Data Overview
Price chart is built with
Anychart
Oxurion NV, a biopharmaceutical company, develops medicines for vascular retinal disorder in Belgium. The company is developing ophthalmic treatments to preserve vision for patients geographic atrophy and wet age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.
Prev. Close
0.0024
Open
0.0025
High
0.0026
Low
0.0023
52 wk Range
0.002-0.0244
Market Cap
338 K
Shares Outstanding
141 M
Revenue
555 K
EPS
0
Beta
-0.085
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oxurion NV data using free add-ons & libraries
Get Oxurion NV Fundamental Data
Oxurion NV Fundamental data includes:
- Net Revenue: 555 K
- EBITDA: -3 255 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-28
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oxurion NV News
New
Oxurion Discloses Topline Data from KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
Regulated information – Inside information Despite Prior Positive Data, THR-149 Did Not Demonstrate Improvement in Vision Oxurion’s Board has Decided to Take Necessary Steps to File for Bankrupt...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunit...
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunit...
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year
Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapie...
Get Oxurion NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
